Brett Jackson is an associate in the firm’s Business Law Department and a member of its Technology group. Mr. Jackson represents startup and later-stage companies in the software, technology and life sciences industries throughout their corporate life cycle, with a particular focus on mergers, acquisitions, financings, royalty transactions and other strategic transactions. He also represents venture capital and private equity funds focusing on technology and life sciences companies. He joined Goodwin in 2018.

Areas of Practice
Domaines D’Expertise





Representative Matters



Financings/General Corporate Counsel
  • EQRX in its $200 million Series A financing
  • Starburst Data, a database company, as outside general counsel and in its equity financings, including a $42 million Series B financing with Coatue Management
  • Current, an online banking and payments company, as outside general counsel and in its equity financings, including its $20 million Series B financing with Wellington
  • Reggora as outside general counsel and in its $10 million Series A financing with Spark Capital
  • A global venture capital firm in its $15 million investment in a Canadian biotechnology company
  • A pharmaceutical research company in its $25 million Series A financing
  • Polaris Partners and TenEleven Venture Fund in their investment in Sonrai Security’s Series A financing
Mergers and Acquisitions
  • eVariant in its sale to Healthgrades
  • Flywheel in its sale to WP Engine
  • Abide Therapeutics in its sale to Lundbeck
  • Cobalt Biomedicine in its sale to Sana Biotechnology
  • OpenExchange in its acquisition of KnowledgeVision Systems
  • Stockholders of New England Treatment Access in its sale to Surterra Wellness
  • Vensun Pharmaceuticals in its sale to Strides Pharma
  • Ampersand Capital Partners in its acquisition of Pacific Biomarkers
  • Webster Capital in its acquisition of Guardian Healthcare Providers
  • Sunstone Partners in its acquisition of TriNimbus Technologies
  • WeTransfer in its acquisition of assets of FiftyThree
  • Cerberus Capital Management in its acquisition of assets of Club Exploria Resorts*
  • PEN America in its acquisition of PEN USA*
Royalty-Based Financings
  • Royalty Pharma, a leading investor in pre-approval royalties, in its $827 million acquisition of Ligand Pharmaceuticals’ royalties on sales of Promacta and its $255 million acquisition of Agios Pharmaceuticals’ royalties on sales of IDHIFA
  • An investor in its approximately $100 million acquisition of a partial interest in the royalty stream of a prostate cancer medication
  • Chiasma in its $75 million royalty financing with HealthCare Royalty Partners
Capital Markets
  • Plug Power in its $23.5 million registered direct offering
  • Surface Oncology in its $80 million “at-the-market” offerings
  • Albertsons in its corporate restructuring and its $2.5 billion exchange offer*
  • FuelCell Energy in its $40 million registered direct offering*
  • Cerberus Capital Management in its $27 million public secondary offering of shares of BlueLinx Holdings*

* Denotes experience prior to joining Goodwin.

Professional Experience

Prior to joining Goodwin, Mr. Jackson was an associate at Schulte Roth & Zabel LLP in New York, where he was a member of the M&A and Securities Practice group and represented private investment funds, publicly traded companies, and privately held companies in connection with a wide range of corporate matters, including mergers and acquisitions, shareholder activism, securities and capital markets transactions, and corporate governance issues.

In The News









J.D., 2016
Fordham University School of Law
(magna cum laude)
M.A., 2013
Trinity College
B.A., 2009
Trinity College



New York
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique